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Abstract
Background: Intermittent preventive treatment in infants (IPTi) has been shown in randomized trials to reduce malaria-
related morbidity in African infants living in areas of high Plasmodium falciparum (Pf) transmission. It remains unclear
whether IPTi is an appropriate prevention strategy in non-African settings or those co-endemic for P. vivax (Pv).
Methods and Findings: In this study, 1,121 Papua New Guinean infants were enrolled into a three-arm placebo-controlled
randomized trial and assigned to sulfadoxine-pyrimethamine (SP) (25 mg/kg and 1.25 mg/kg) plus amodiaquine (AQ)
(10 mg/kg, 3 d, n= 374), SP plus artesunate (AS) (4 mg/kg, 3 d, n= 374), or placebo (n= 373), given at 3, 6, 9 and 12 mo.
Both participants and study teams were blinded to treatment allocation. The primary end point was protective efficacy (PE)
against all episodes of clinical malaria from 3 to 15 mo of age. Analysis was by modified intention to treat. The PE
(compared to placebo) against clinical malaria episodes (caused by all species) was 29% (95% CI, 10–43, p#0.001) in children
receiving SP-AQ and 12% (95% CI,211 to 30, p= 0.12) in those receiving SP-AS. Efficacy was higher against Pf than Pv. In the
SP-AQ group, Pf incidence was 35% (95% CI, 9–54, p= 0.012) and Pv incidence was 23% (95% CI, 0–41, p= 0.048) lower than
in the placebo group. IPTi with SP-AS protected only against Pf episodes (PE = 31%, 95% CI, 4–51, p= 0.027), not against Pv
episodes (PE = 6%, 95% CI, 224 to 26, p= 0.759). Number of observed adverse events/serious adverse events did not differ
between treatment arms (p.0.55). None of the serious adverse events were thought to be treatment-related, and the
vomiting rate was low in both treatment groups (1.4%–2.0%). No rebound in malaria morbidity was observed for 6 mo
following the intervention.
Conclusions: IPTi using a long half-life drug combination is efficacious for the prevention of malaria and anemia in infants
living in a region highly endemic for both Pf and Pv.
Trial registration: ClinicalTrials.gov NCT00285662
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Introduction
Malaria and anemia are major causes of morbidity and
mortality in children in tropical countries [1]. Several preventive
strategies have proven to be effective in reducing this burden, such
as insecticide-treated bed nets [2], indoor residual spraying [3], or
prompt diagnosis and treatment of malaria with artemisinin
combination therapy [1,4]. Additionally, the preventative admin-
istration of a full treatment course of antimalarial drugs at fixed
intervals regardless of illness episodes, named intermittent
preventive treatment (IPT), has been shown to reduce malaria-
related morbidity in different high risk groups [5,6]. This strategy
is increasingly widely used in pregnant women (IPTp) [7,8], with a
positive effect on antenatal parasitemia, placental malaria,
maternal hemoglobin (Hb), birth weights, and newborn malaria
infections [7,9]. Several studies have shown that IPT is effective in
reducing malaria incidence when given to infants at the time of
routine immunizations (IPTi), or to older children in areas where
malaria transmission is highly seasonal (IPTc) [10–13].
In the past 10 y, eight randomized controlled trials have
investigated IPTi in different African countries, with various drug
regimens. Sulfadoxine-pyrimethamine (SP), dispensed as a single
dose three or four times during the first year of life, is the most
studied drug and has been associated with a protective efficacy (PE)
against clinical malaria episodes of 30% (ranging from 20% to 59%)
in populations where SP resistance is not extensive. It also reduced
the risk of anemia by 21% in these trials [10]. In all but one trial the
preventative effect of the IPTi dose was restricted almost exclusively
to the first 5 wk after an individual IPTi dose, with little effect
thereafter [10]. While IPTi with SP retains efficacy in areas with
moderate SP resistance [14,15], SP has failed to prevent malaria in
areas with very high resistance levels [16,17]. Based on this
evidence, the World Health Organization recommends IPTi as a
suitable malaria control intervention in areas of high malaria
burden and low-to-moderate SP resistance [18].
To date, all reported IPTi studies have been carried out
exclusively in sub-Saharan Africa in populations where Plasmodium
falciparum (Pf) is the predominant parasite and P. vivax (Pv) is
uncommon because of the high prevalence of Duffy negativity
[19]. However, in highly endemic areas of the Southwest Pacific
[20,21], Southeast Asia [22], the Americas [23], and the horn of
Africa [24], Pv is a major cause of malaria morbidity, including
severe illness and death in young children in particular. Therefore,
although IPTi may have significant benefits in these regions, to
date there are no data of which we are aware on IPTi efficacy in
non-African settings, or on the use of IPTi for malaria due to P.
vivax. Results from Africa cannot be easily extrapolated to other
settings because of differences in the biology of Pf and Pv [25], in
particular the ability of Pv to relapse from long-lasting liver stages,
and also the ability of Pv to quickly acquire resistance to SP [26].
In order to determine the efficacy of IPTi in reducing the
burden of malaria (all cause as well as Pf and Pv specific) and
anemia in a Pf and Pv co-endemic setting, we undertook a three-
arm randomized placebo-controlled trial of IPTi in an area of
Papua New Guinea (PNG) that is highly endemic for both Pf and
Pv. We tested two different drug regimens, combining a long-
acting drug (SP) with either 3 d of amodiaquine (AQ) (another
long half-life drug) or 3 d of artesunate (AS) (a short half-life drug),
given in conjunction with routine immunization activities. These
two drug regimens were chosen for two reasons: (1) they were the
first and second line treatments in PNG at the time of the
commencement of the study, facilitating their possible implemen-
tation into PNG standard practice as treatments for IPTi, and (2)
the comparison allows differentiation between the importance of
potentiallyimproved clearance of existing infections (using SP-AS)
versus better prevention of new infections post-treatment (using
the long-acting combination of SP-AQ).
Methods
Trial Design, Sites, and Study Participants
We undertook an individually randomized placebo-controlled
trial of two different drug regimens (SP [single dose] in
combination with either 3 d of AQ [SP-AQ] or 3 d of AS [SP-
AS]) given as IPTi at routine vaccination time points (3, 6, and
9 mo) and at 12 mo in conjunction with routine vitamin A
supplementation as part of the World Health Organization’s
Expanded Programme on Immunization (EPI) in PNG. Partici-
pants, field teams, and investigators were all blinded with respect
to treatment allocation. The efficacy of the intervention was
assessed for a 12-mo period from enrollment to a primary assess-
ment time point at 15 mo of age, with a 6-mo extended follow-up
(15–21 mo) to assess potential rebound.
The study was carried out between 6 June 2006 and 14 May
2010 on the north coast of PNG in the Mugil area of Sumkar
District, Madang Province. The study site included 20 villages
situated in an ,400-km2 coastal area 30–60 km north of Madang
town. The region receives over 3,000 mm of rainfall annually,
with a short dry season (June to October), and is considered to
have hyper-endemic malaria [27,28]. Study villages are serviced
by two major health centers (Mugil and Alexishafen) and several
aid posts that are responsible for delivering EPI through monthly
outreach clinics. Although ownership of bed nets was relatively
high (.50%), until the start of free long-lasting insecticide-treated
net distribution by the national malaria program in late 2008, the
majority of the population in the study site were using untreated
nets.
Originally, the trial was started as a two-site study, with a
second site in Wosera (East Sepik Province). However, an interim
analysis performed mid-study found that the incidence of malaria
was dramatically different between the two sites, restricting the
comparability of the two sites. Consequently, enrollments were
ceased in Wosera in May 2008 and, in line with a revised sample
size calculation, enrollments at the Madang site were increased to
334 children per arm. The data from the Wosera cohort were
subsequently used only for an overall safety analysis (Table S1).
The study was carried out in accordance with Good Clinical
Practice (ICH GCP E6) guidelines and externally monitored by two
independent monitors and the Data Safety Monitoring Board. The
study was approved by the PNG Medical Research Advisory
Committee (MRAC number 05.20). The trial was registered on
http://www.clinicaltrials.gov (number NCT00285662) and formed
part of the IPTi Consortium (http://www.ipti-malaria.org) [29].
Randomization, Blinding, and Treatment Allocation
Children were enrolled if they fulfilled the following criteria: (1)
permanent resident of the area, (2) aged 3 (61) mo old, (3) no
disability, (4) no chronic illness, (5) no known allergy to study
drugs, (6) Hb.5 g/dl, and (7) no severe malnutrition (defined by
the PNG national guidelines as a weight less than 60% of the
Harvard reference weight-for-age value [30]). After enrollment
children were randomly allocated to the placebo, SP-AQ, or SP-
AS treatment group using a pre-assigned list. Randomization lists
were prepared by independent statistician using SAS software and
consisted of assignments in blocks of 12, each comprising a list of
the same 12 letters in random order. The three arms of the trial
were each assigned four randomly selected letters from among the
twelve, which were used to label the packaging of the tablets. The
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code list was held by the statistician in a locked drawer until
completion of the trial. Individual allocation codes were contained
in pre-prepared opaque envelopes, which were opened only after a
child was allocated to the next available ID number.
SP, AS, AQ, and their respective placebos were pre-packaged in
individual blisters by the drug manufacturers (SP and AS, IPCA;
AQ, Kinapharma). Study drugs and placebo were identical in
appearance and color, but as drugs were administered with sweet
syrup no attempt was made to match the moderately bitter taste of
AQ. The quality of all drugs and corresponding placebo was
independently verified. Study drugs and placebo were assigned to
the respective treatment codes by an independent technician. The
entire study team and principal investigators remained fully
blinded for the entire study period.
Clinical Study Procedures
The three different study interventions were (1) SP-AQ, a single
dose of SP (25 mg/kg sulfadoxine and 1.25 mg/kg pyrimeth-
amine) combined with 3 d of AQ (10 mg/kg) plus 3 d of AS
placebo; (2) SP-AS, a single dose of SP plus 3 d of AS (4 mg/kg)
plus 3 d of AQ placebo; (3) matching placebos for all three drugs.
The tablets were split (quarters or halves) according to the weight
(in kilograms) of each child. The two treatment arms corresponded
to the first and second line treatments of the PNG national
standard guidelines for malaria at that time.
The intervention was delivered four times during the first year
of life alongside the EPI at 3, 6, 9, and 12 mo of age (Table 1). The
drugs were crushed and mixed with water and sweet syrup
(Golden Crush Cordial, Coca-Cola Amatil) for easy administration
with spoon or syringe. The first day dose was administered by
study staff. The children were monitored closely, and if they
vomited within 30 min of receiving treatment, the dose was
repeated. The second and third doses were given by the carer at
home without direct supervision. Adherence and potential adverse
reactions to the study drugs were assessed by community reporters,
and an adherence rate of .90% was reported (data not shown).
The parents or guardians of potential study participants were
contacted during monthly routine EPI clinics run jointly by study
staff and health center staff when the child was 1–2 mo of age. The
study was explained in detail to the parents through both
individual and community awareness meetings. An information
brochure and consent form in English and in the local language
(Pidgin) was given to the parents to take home for further
discussion.
A child who met the inclusion criteria was formally enrolled
during the next clinic visit, when the child was 3 mo of age
(61 mo) and after at least one parent gave written consent. Upon
enrollment, a concise medical history including bed net use,
possible disabilities, and presence of acute illness was performed. A
brief physical examination was done, including measurement of
weight. Table 1 summarizes what occurred at different visits
during the trial.
Throughout the study period, a passive case detection system
was maintained at the Mugil health center and three outlying
clinics where study participants received treatment free of charge.
Each illness episode was assessed by study staff using a standard
case report form. In the case of history of fever within the past
48 h or an axillary temperature .37.5uC, a rapid malaria diag-
nostic test (ICT Combo) was performed, two blood smears and
250 ml of whole blood were collected, and Hb level was measured
using a portable HemoCue 201 machine. Only infants positive for
malaria on the rapid diagnostic test were treated with artemether/
lumefantrine (Coartem). The children with moderate to severe
anemia (Hb,8 g/dl) received iron supplementation (ferrous
sulfate, 5 mg/kg daily for 6 wk). All other illnesses were treated
according to the standard treatment guidelines of PNG. Children
presenting with any danger signs or symptoms were referred to the
health center for admission and treatment. Study participants who
attended after hours were treated by health center staff based on
presumptive diagnosis. In such cases, study staff recorded the
reason for admission and (when possible) performed a finger prick
to check parasitemia and Hb the next day.
All illness episodes were considered adverse events (AEs) and
were graded by the study clinicians according to severity from
grade 1 (less severe) to grade 3 or as a serious adverse event (SAE;
life-threatening or deadly, resulting in disability/incapacity, or
Table 1. Summary of scheduled patient contacts during study follow-up.
Type of Visit Age (Months)
2 3 6 9 12 15 18 21
Pre-screening X
IPTi treatment IPTi 1 IPTi 2 IPTi 3 IPTi 4
Primary efficacy assessment X
Follow-up X
Final assessment X
Passive case detection X X X X X X X
Immunization OPV 3 OPV 4
HBV 3
DPT 2 DPT 3
Meas 1 Meas 2
Vit A Vit A
During schedules visits
Blood collection (finger prick) 500 ml 250 ml 250 ml 250 ml 1 ml 250 ml 250 ml
Hb levels X X
DTP, diphteria, pertussis, tetanus vaccine; HBV, hepatitis B vaccine; Meas, measles vaccine; OPV, oral polio vaccine; Vit A, oral vitamin A supplementation.
doi:10.1371/journal.pmed.1001195.t001
Prevention of P. falciparum and P. vivax by IPTi
PLoS Medicine | www.plosmedicine.org 3 March 2012 | Volume 9 | Issue 3 | e1001195
presenting with specific clinical/laboratory features such as those
that characterize important hematological disorders [as defined by
the IPTi Consortium]). Hospital admissions that did not fulfill the
criteria of SAE were considered grade 3. The study clinicians
assessed all SAEs and causality of AEs. SAEs and AEs possibly or
certainly related to the intervention were reported to the Data
Safety Monitoring Board, which assessed grade and causality using
IPTi Consortium guidelines.
Diagnosis of Malaria Infections
All blood slides were read by two expert microscopists. In case
of discrepancies, a third read was performed. Thick blood films
were examined by light microscopy for 200 thick-film fields (under
1006oil immersion lens) before being declared infection-negative.
Slides were scored as light-microscopy-positive for an individual
Plasmodium species, if the species was detected independently by at
least two microscopists. Additionally, if the final slide readings
were discrepant compared to PCR results (positivity and species), a
final confirmatory read by a senior microscopist was performed.
Parasite densities were recorded as the number of parasites per
200 white blood cells and converted to the number of parasites/
microliter assuming 8,000 white blood cells/microliter [3]. Final
parasite densities were obtained by calculating the geometric mean
of positive reads.
Blood samples were collected from finger pricks in tubes coated
with ethylenediaminetetraacetic acid and/or in plain tubes (15-mo
visit only). Upon arrival in the laboratory, samples were separated
into plasma or serum and cell pellet. Plasma and serum were
stored at 280uC until further use. DNA was extracted from cell
pellets using the QiaAMP 96 extraction kit (Qiagen) and the 96-
well Genomic DNA Extraction Kit (Favorgen).
The presence of each of the four human malarial species was
assessed in all blood samples using a semi-quantitative post-PCR
ligase detection reaction/fluorescent microsphere assay (LDR-
FMA) [31]. This assay combines PCR amplification of the small
subunit ribosomal RNA gene (491- to 500-bp fragments) using
genus-specific primers, followed by a multiplex species-specific
ligation detection reaction. The design and sensitivity of this assay
have been described previously [31,32]. The threshold of positivity
of the reactions for each species was determined monthly using the
mean value obtained for the negative controls (for each species),
plus three times the value of its standard deviation. Samples with
low-positive values (,[threshold+86 standard deviation]) were
double-checked and considered as positive only if the result was
confirmed.
Sample Size Calculations
Based on a predicted incidence rate of 1.2 episodes/child/year
(0.7 for Pf and 0.5 for Pv), a power of 90% and alpha= 0.025, a
sample size of 250 children per arm was estimated to be necessary
to find at least a 28% reduction in the incidence of all malaria
episodes, a 30% reduction in the incidence of Pv, and a 35%–37%
reduction in the incidence of Pf episodes. Assuming a drop out of
participants of 20% in conjunction with a fall in incidence of
malaria of 30% to 50% due to long-lasting insecticide-treated net
introduction through the national program in November 2008, a
final adjusted sample size of 366 children per arm, or 1,100
children in total, was calculated.
Statistical Methods
The analysis was performed both by modified intention to treat
(mITT) and according to protocol (ATP). The mITT population
includes all randomized children in Mugil that received at least
one dose of IPTi or placebo (i.e., 1,121 of 1,125 children).
Following the mITT principle, participants were analyzed
according to the preventive treatment they were assigned to at
randomization. In the ATP analysis, the population includes all
randomized participants who received at least three IPTi
treatments (each given within 4 wk after the scheduled treatment
time point) and were under passive surveillance for the entire 12-
mo period.
The primary objective of the trial was to evaluate the protective
effect of the two IPTi regimens. The primary outcome was
measured as the incidence of symptomatic malaria due to any
Plasmodium species from 3 to 15 mo of age. Secondary outcomes
included (1) the specific incidence of symptomatic malaria due to
Pf or Pv from 3 to 15 mo of age, (2) the incidence of symptomatic
malaria (any, Pf, and Pv) from 15 to 21 mo (i.e., ‘‘rebound’’), (3)
the incidence of moderate-to-severe anemia (Hb,8 g/dl) and
severe anemia (Hb,5 g/dl) from 3 to 15 mo and 15 to 21 mo,
and (4) the prevalence of malaria parasitemia at 15 and 21 mo.
Symptomatic malaria was defined as history of fever or axillary
temperature $37.5uC and a positive blood smear or a positive
rapid diagnostic test, confirmed by positive PCR. The incidences
were compared between groups using negative binomial regression
to take into account possible extra-Poisson variation due to frailty
at the individual level. Analyses were adjusted by sex, number of
IPTi treatments received, season of enrollment (wet versus dry),
average bed net use, and site (grouped by 12 recruitment zones).
The time at risk was calculated starting on the date of enrollment
until the date defined according to the analysis, or until the
participant was withdrawn from the study. An arbitrary period of
28 d was excluded after each malaria episode. The same
methodology was used for evaluating of the incidence of
moderate-to-severe (Hb,8 g/dl) and severe anemia (Hb,5 g/
dl). Efficacy results are presented as either incidence rate ratio
(IRR) or PE (PE= 12IRR).
The risk of malaria within 35 d following the administration of
each of the treatment doses was investigated by calculating
incidence rates and hazard ratios using a Cox regression model.
Differences in prevalence of infection at 15 and 21 mo were
evaluated using logistic regression.
The analyses were performed in Stata version 11 (StataCorp).
Results
From 6 June 2006 to 14 May 2010, 1,125 3-mo-old infants were
enrolled, randomized, and followed-up in the trial in the Mugil area
of Madang Province (Figure 1). Four infants were retrospectively
excluded from the analysis as they were already receiving
antimalarial treatments at the time of all IPTi visits and therefore
did not receive any IPTi treatment doses. In all, 374 infants were
allocated to the SP-AQ group, 374 to the SP-AS group, and 373 to
the placebo group (Figure 1). A total of 1,079 (96%) participants
completed follow-up to 15 mo, whereas 857 (76%) completed the 6-
mo post-treatment follow-up (i.e., 15–21 mo).
The baseline characteristics of all study infants were similar across
the three treatment arms (Table 2). No significant imbalances were
observed between the three groups. In the final multivariate models,
gender, village of residence, average insecticide-treated net use,
and season of recruitment were included. A total of 939 children
who received three or four IPTi treatments were included in the
ATP population, with no significant imbalances between groups
(Table S2).
Protective Efficacy
The incidence of clinical malaria between the first dose at 3 mo
and 15 mo in the placebo arm was 1.07 per person-year at risk
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(PYAR) overall, and 0.28 and 0.82 for Pf and Pv, respectively. In
mITT analyses, the incidence of all cases of malaria was 29%
(95% CI, 10–43, p#0.001) lower in the SP-AQ group as compared
to placebo, but not significantly reduced in the SP-AS group as
compared to placebo (point estimate for change 12%, 95% CI,
211 to 30, p=0.12). The PE was higher against Pf than Pv in both
groups (Table 3). In the SP-AQ group, Pf incidence was reduced
by 35% (95% CI, 9–54, p=0.012) and Pv incidence by 23% (95%
CI, 0–41, p=0.048) in comparison to placebo. In contrast, the SP-
AS group showed a significant reduction only for incidence of Pf
(PE= 31%, 95% CI, 4–51, p=0.027), not for incidence of Pv
(PE= 4%, 95% CI, 226 to 24, p=0.759).
Estimates of protection were higher when only children with
three or more IPTi treatments were considered (i.e., ATP analyses;
Table 3). Regular administration of SP-AQ reduced malaria
episodes by 38% overall (95% CI, 20–52, p,0.001), with
reductions of 49% (95% CI, 26–65, p,0.001) and 31% (95%
CI, 9–48, p=0.010) for Pf and Pv malaria episodes, respectively.
Administration of SP-AS resulted in a 23% reduction in all
malaria episodes (95% CI, 1–40, p=0.041), with a statistically
significant reduction for Pf (46% lower, 95% CI, 22–62, p=0.001)
but not for Pv (point estimate for change 12%, 95% CI,216 to 34,
p=0.355).
Comparable effects were seen when more specific definitions for
Pf (i.e., parasite density .2,500/ml) and Pv (i.e., parasite density
.500/ml) [33] were applied (Table 3). In the ATP cohort, in the
SP-AQ arm only, a substantially higher protection was observed
against higher density Pf (PE= 65%, 95% CI, 43–79, p,0.001)
but not against higher density Pv. The results for the mITT cohort
are comparable.
IPTi with SP-AQ or SP-AS also provided protection against
moderate-to-severe anemia (Hb,8 g/dl; Table 3). In the ATP
population, the PE increased to 41% (95% CI, 18–58, p=0.002)
in the SP-AQ group and 34% (95% CI, 8–53, p=0.013) in the SP-
AS group. Few cases of severe anemia (,5 g/dl) were observed
during the study. In the ATP analysis, there were seven cases in
the placebo group, one in the SP-AQ group, and two in the SP-AS
group (p=0.04). Results for the mITT population were of similar
magnitude, although in general the estimates obtained were lower
and not statistically significant (p=0.09–0.13) (see Table 3).
Figure 1. Trial profile. incomplete FU, incomplete follow-up (i.e., the study was terminated before the participant completed the 21-mo follow-up
time period); LTF, lost to follow-up.
doi:10.1371/journal.pmed.1001195.g001
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Adjustment for gender, village of residency, season of recruit-
ment, and use of bed nets did not significantly alter estimates of PE
(Figure 2).
Post- and Inter-Dose Efficacy
The combined PE in the 35 d following the administration of
each IPTi treatment dose showed a reduction of 80% (95% CI,
67–88, p,0.001) with SP-AQ and 63% (95% CI, 45–76, p,0.001)
with SP-AS for all malaria infection (Table 3). SP-AQ had slightly
lower PE against Pf (72%, 95% CI, 33–87, p,0.001) than against
Pv (83%, 95% CI, 70–90, p,0.001), whereas SP-AS was more
efficacious against Pf (82%, 95% CI, 53–93, p,0.001) than against
Pv (59%, 95% CI, 47–73, p,0.001). Both SP-AQ (PE= 43%, 95%
CI, 13–63, p=0.010) and SP-AS (PE=38%, 95% CI, 6–59,
p=0.026) were associated with a significant reduction in the
incidence of Pf malaria between IPTi doses (i.e., the period from
35 d after a treatment dose to the next IPTi dose). However, no
effect on the incidence of Pv malaria was observed for either
treatment group beyond the first 35 d (Table 3).
Safety
A total of 6,165 AEs and 275 SAEs were observed during the
intervention period, with no significant difference between
treatment arms (Table 4). None of the SAEs were judged (by
the Data Safety Monitoring Board and IPTi Safety Working
Group) to be intervention-related. One child in the placebo group
experienced a non-severe (grade 1) skin rash a few days following
administration of the second IPTi dose. Vomiting was reported in
2% of infants receiving SP-AQ, 1.4% of infants receiving SP-AS,
and 0.6% of infants receiving placebo (p=0.001).
In total, ten deaths occurred among study participants. One was
excluded from the analysis because he/she did not receive any IPTi
treatment dose. Out of the nine study deaths, seven occurred during
the intervention period (i.e., 3–15 mo of age). Of these, six occurred
in the placebo group, one in the SP-AS group, and none in the SP-
AQ group (p=0.011). An additional two deaths (one each in the SP-
AS and placebo groups) were observed during post-intervention
follow-up. The likely diagnoses for the nine deaths were as follows: one
severe Pv malaria (parasite density of 12,200/ml) with severe anemia
and possible lower respiratory tract infection (severe respiratory
distress and cough), three lower respiratory tract infections, two severe
dehydrations, one meningitis, and two unknown diagnoses.
Post-Intervention Risk
The incidence of clinical malaria between 15 and 21 mo was
1.09 PYAR overall and 0.43 and 0.70 for Pf and Pv, respectively.
No evidence of a ‘‘rebound effect’’ was observed in the 6 mo
following the end of the intervention at the age of 15 mo. In both
mITT and ATP populations, no significant difference in incidence
of all malaria episodes was observed between treatment and
Table 2. Baseline characteristics of study participants—intention-to-treat cohort.
Characteristic Subcategory Placebo SP-AQ SP-AS
Total n 373 374 374
Female 192 (51.5%) 166 (44.4%) 187 (50%)
Village area Biranis 18 (4.8%) 20 (5.4%) 18 (4.8%)
Megiar 20 (5.4%) 17 (4.6%) 22 (5.9%)
Aronis Garup Wasabamal Zizzi 41 (10%) 35 (9.4%) 42 (11.2%)
Basken Dimer 77 (20.6%) 74 (19.9%) 72 (19.3%)
Bunu Kusen Mugil 38 (10.2%) 54 (14.4%) 54 (14.4%)
Matukar Wasab 38 (10.2%) 31 (8.3%) 24 (6.4%)
Dylup 20 (5.4%) 29 (7.8%) 22 (5.9%)
Karkum 16 (4.3%) 8 (2.1%) 20 (5.6%)
Mirap 17 (4.6%) 23 (6.2%) 31 (8.3%)
Sareng 30 (8%) 21 (5.6%) 23 (6.2%)
Taldig 41 (11%) 48 (12.8%) 33 (8.8%)
Rempi 17 (4.6%) 14 (3.7%) 13 (3.5%)
Slept under bed net last 2 wka 308 (82.8%) 299 (80%) 305 (82%)
Recruitment during rainy season (October–June)a 303 (73.5%) 301 (73.0%) 301 (72.5%)
Mean age at enrollment (days)a 96 (15) 99 (18) 98 (16)
Weight (kilograms)a 5.9 (0.8) 6.0 (0.9) 6.0 (0.8)
Hb (grams/decaliter)a 9.5 (1.0) 9.5 (1.2) 9.5 (1.1)
Prevalence of parasitemia at baseline (light microscopy) All species 14 (3.8%) 30 (8%) 24 (6.4%)
Pf 7 (1.9%) 13 (3.5%) 9 (2.4%)
Pv 7 (1.9%) 17 (4.5%) 15 (4%)
Prevalence of parasitemia at baseline (PCR) All species 69 (18.5%) 87 (23.3%) 75 (20.1%)
Pf 17 (4.6%) 20 (5.4%) 15 (4%)
Pv 52 (13.9%) 74 (19.8%) 63 (16.8%)
Data are n (percent) unless otherwise indicated.
aData are mean (standard deviation).
doi:10.1371/journal.pmed.1001195.t002
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intervention groups (Table 4; p=0.56). Similarly, no significant
differences in incidence of Pf malaria, Pv malaria, and anemia
were observed.
Prevalence of Parasitemia during Follow-Up
The prevalence rates of both Pf and Pv increased from 1.5% and
8.5% at 6 mo to 3.0% and 15.8% at 15 mo and 4.4% and 20.3%
at 21 mo, respectively, when detected by microscopy (Figure 3).
Using molecular diagnosis, prevalence of Pf and Pv was higher,
and also increased with age (Figure 3). At 15 mo, the prevalence of
Pf was significantly lower in the two treatment arms (p=0.037) by
light microscopy but not by LDR-FMA. No significant differences
in prevalence were observed between treatment arms at 21 mo or
any other time point for either Pf or Pv. Infections with P. malariae
and P. ovale were rare by microscopy (overall prevalence P.
malariae: 0.1%, P. ovale: 0.0%) and LDR-FMA (P. malariae: 1.0%, P.
ovale: 0.4%).
Discussion
This study in PNG infants provides the first evidence of which
we are aware for the efficacy of IPTi with SP-based regimens for
the prevention of malaria and anemia in a non-African
population, including data on the efficacy against Pv malaria.
IPTi with a combination of SP plus 3 d of AQ resulted in a 29%
decrease in all malaria episodes and a 25% decrease in episodes of
moderate-to-severe anemia. PE was higher in children who
received at least three doses of IPTi (38% for all malaria and
41% for anemia). In line with local resistance patterns and SP-AS
pharmacokinetic properties, SP-AS was found to be inferior to SP-
AQ. Overall, the efficacy of IPTi with SP-AQ in PNG infants is
comparable to the 30% efficacy observed in other studies of
African infants receiving IPTi with SP [10]. Importantly, SP-AQ
has significant efficacy against both Pf and Pv malaria. Both IPTi
treatments were safe and well tolerated. Therefore, these findings
provide essential proof-of-principle evidence for the safety and
efficacy of IPTi outside Africa, which has important implications
for public health policy in non-African settings.
Prevention of Malaria
Overall, IPTi with SP-AQ was more effective in preventing Pf
than Pv malaria (mITT 35% versus 23%, ATP 49% versuss 31%),
and was more effective than SP-AS for Pf and Pv malaria. This was
not unexpected. Two recent African clinical trials of IPTi have
investigated alternative drug regimens, including at least one long
half-life antimalarial such as mefloquine (125 mg single dose), a
combination of SP (single dose) plus 3 d of AS, or AQ plus AS.
These treatments had protective efficacies ranging from 26% to
38% [16,34] and were comparable to those in earlier SP trials.
However, a shorter acting combination, dapsone/chlorproguanil
failed to significantly reduce the burden of malaria or anemia
[16,34]. Similarly, in the earlier IPTi SP trials, the preventative
effect of IPTi SP was almost entirely due to a reduction of malaria
in the first 5 wk after treatment [10,35]. Together, these results
SP-AQ
IPTi at  3, 6, 9 
and 12 months
SP-AS
all malaria episodes
ITT PE: 28% [9, 43]
ATP PE: 37% [20, 51]
Pf infections
ITT PE: 35% [10, 43]
ATP PE: 50% [27, 65]
Pv infections
ITT PE: 22% [-1, 39]
ATP PE: 30% [7, 47]
all malaria episodes
ITT PE: 11% [-11, 29]
ATP PE: 22% [1, 39]
Pf infections
ITT PE: 30%  [3, 49]
ATP PE: 45% [21, 62]
Pv infections
ITT PE: 4% [-24, 25]
ATP PE: 12% [-16, 33]
ITT: Intention to treat
ATP: as to protocol
Anemia (hb<8g/dl)
ITT PE: 22% [-5, 42]
ATP PE: 34% [8, 53]
Anemia (hb<8g/dl)
ITT PE: 24% [-2, 43]
ATP PE: 41% [18, 58]
Figure 2. Summary of IPTi preventive efficacy against malaria at 15 mo of age adjusted for sex, place of residence, season of
enrollment, and average insecticide-treated net use.
doi:10.1371/journal.pmed.1001195.g002
Prevention of P. falciparum and P. vivax by IPTi
PLoS Medicine | www.plosmedicine.org 8 March 2012 | Volume 9 | Issue 3 | e1001195
suggest that IPTi works mainly through a prophylactic effect,
achieved by long-acting drugs preventing new infections, rather
than by eradicating existing parasitemia [35]. Consistent with the
African results, in the present study both SP-containing regimens
had similarly high protective effect against Pf for the first 35 d
(72%–82%) as well as a moderate inter-dose effect, resulting in an
overall efficacy of IPTi against Pf that was towards the higher end
of those found in African studies [10,16,34].
SP-AQ also prevented 83% of Pv episodes in the first 35 d
following treatment, indicating a similar post-treatment prophy-
lactic effect, but the overall efficacy of IPTi against Pv malaria was
lower than for Pf. SP-AS, however, showed significantly less post-
treatment prophylactic effect (PE= 59%) and no effect against Pv
malaria overall. The most probable reasons for this are the ability
of Pv to relapse from long-lasting liver stages [36] and higher levels
of SP resistance in Pv. Pv strains from New Guinea are thought to
relapse very frequently [37], and Pv blood-stage infections are
therefore re-established soon after drug treatment. In a concur-
rently conducted drug trial, 49% of PNG children 0.5–5 y treated
with SP-chloroquine (3 d) for Pv malaria had recurrent Pv
parasitemia, and an additional 18% had a recurrent Pv clinical
episode by day 42, while 26% and 6% of children treated for Pf
malaria had recurrent Pf parasitemia and clinical episodes,
respectively [38].
The differential efficacy of IPTi with SP-AQ and SP-AS for the
prevention of Pf and Pv malaria is consistent with the
pharmacokinetic properties of the drugs used and previously
observed drug resistance patterns. PCR-corrected day 28 in vivo
failure rates from studies conducted concurrently or just prior to
the trial were 10.3% for SP-AQ [39] and 10.0% for SP-AS [38]
for Pf, and 3.6% for SP-AQ [40] and 11.8% for SP-AS [41] for Pv.
As SP has never been used as monotherapy in PNG, there are no
estimates of SP in vivo resistance for either Pf or Pv. However,
molecular markers of SP resistance have been analyzed for both
species in the study population. In Pf, the quintuple Pf dihydrofolate
reductase (pfdhfr) 51–59–108/Pf dihydropteroate synthase (pfdhps) 436–
547 mutant genotype is associated with a high degree of drug
resistance [42], while in Pv, the 57L-58R-61M-117T pvdhfr
quadruple mutation (irrespective of pvdhps mutations) has been
associated with increased risk of treatment failure [43,44]. The
high frequency of the quadruple pvdhfr mutation in PNG (52%
[41]) suggests that the clinical efficacy of SP for Pv may be
significantly compromised. In contrast, the absence of quadruple/
quintuple pfdhfr/pfdhps [45] suggests that SP retains substantial
efficacy against Pf.
Although chloroquine-resistant Pv was first described in PNG
[46], there is a significantly higher level of 4-aminoquinoline
resistance present in Pf than in Pv. By the early 1990s, greater
than 35% of Pf cases showed RII and RIII resistance [47], and
mutations underlying chloroquine and AQ resistance were shown
to be highly prevalent [48]. In 2003/2004, SP-AQ was 100%
clinically effective, but recurrent Pv parasitemia was observed in
12% of children treated with SP-AQ [39]. The pvdhfr 57L-58R-
61M-117T/Pv multidrug resistance 1 (pvmdr1) 976F quintuple
mutant genotype has been associated with parasitological failure
[43]. Although the pvmdr1 976F mutation was present in ,70%
Table 4. Safety of IPTi with SP-AQ and SP-AS: adverse events and effect of incidence of malaria and anemia.
Analyses and Endpoints Placebo SP-AQ SP-AS
p-
Valueb
Events PYAR Incidence Events PYAR Incidence IRRa 95% CI Events PYAR Incidence IRRa 95% CI
Safety of IPTi
3–15 mo - mITT cohort
All adverse events 1,353 359.4 3.76 1,348 367.7 3.67 0.97 0.88–1.08 1,353 366.8 3.69 0.98 0.88–1.09 0.867
Serious adverse events 65 362.8 0.18 83 371.0 0.22 1.22 0.83–1.79 81 370.1 0.22 1.20 0.81–1.77 0.550
Clinical malaria
All episodes 171 149.0 1.15 164 155.5 1.05 0.91 0.70–1.20 167 157.2 1.06 0.92 0.70–1.21 0.763
All Pf episodes 65 156.2 0.42 68 162.0 0.42 1 0.68–1.48 74 163.8 0.45 1.08 0.74–1.58 0.907
Pf.2500/ml 41 157.8 0.26 43 163.6 0.26 1.01 0.63–1.62 51 165.0 0.31 1.19 0.76–1.88 0.693
All Pv episodes 115 152.9 0.75 112 158.8 0.71 0.93 0.67–1.30 106 161.1 0.66 0.88 0.63–1.23 0.753
Pv.500/ml 86 154.9 0.56 84 160.6 0.52 0.93 0.63–1.38 78 162.9 0.48 0.87 0.58–1.29 0.779
Anemia
Moderate-to-severe
(Hb,8 g/dl)
42 157.7 0.27 44 163.4 0.27 1.01 0.63–1.61 45 165.4 0.27 1.03 0.64–1.63 0.994
Clinical malaria
All episodes 140 127.4 1.10 138 136,2 1.01 0.91 0.67–1.24 143 134.6 1.06 0.96 0.71–1.30 0.833
All Pf episodes 54 133.1 0.41 56 141.8 0.39 0.97 0.63–1.48 63 140.1 0.45 1.10 0.73–1.67 0.809
Pf.2500/ml 34 134.5 0.25 35 143.2 0.24 0.96 0.57–1.62 44 141.2 0.31 1.25 0.75–2.03 0.560
All Pv episodes 94 130.6 0.72 95 138.9 0.68 0.95 0.66–1.37 91 137.9 0.66 0.92 0.64–1.34 0.911
Pv.500/ml 71 132.2 0.54 72 140.5 0.51 0.94 0.61–1.46 68 139.4 0.49 0.92 0.59–1.43 0.928
Anemia
Moderate-to-severe
(Hb,8 g/dl)
40 134.1 0.30 37 142.9 0.26 0.87 0.43–1.44 39 141.6 0.28 0.93 0.56–1.43 0.862
aModel-based IRR.
bp-Values for comparison across all three treatment groups.
doi:10.1371/journal.pmed.1001195.t004
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of Pv isolates tested in 2006/2007, the predominantly late
occurrence of recurrent parasitemia (i.e., day 28–42) following
treatment with SP-chloroquine indicates that 4-aminoquinolines
retained good clinical and at least partial parasitological efficacy
[41].
Given the high level of AQ resistance and the very short half-
life of AS [49], the efficacy of IPTi for the prevention of Pf is
likely to be largely due to the effect of SP. The high level of
preventative efficacy for 35 d is consistent with the terminal
elimination half-life (t1/2b) of 15.6 and 9.1 d for pyrimethamine
and sulfadoxine, respectively, in PNG infants [50]. With SP
having a greatly reduced efficacy against Pv, the success of IPTi
against Pv malaria relies largely on the efficacy of the partner
drug. Whereas Pv parasites are efficiently cleared by SP-AS, the
short half-life of AS provides no post-treatment prophylactic
effect, and recurrent Pv infections are very common [38]. AQ on
the other hand has a half-life of ,9 d [51], and a 3-d course
should therefore effectively suppress sensitive parasites effectively
for 4–5 wk. The lack of any protective effect of SP-AS against Pv
but not Pf adds further evidence to the observation that while SP
can retain a considerable effect at low-to-moderate levels of
resistance [14], it loses its prophylactic activity at high levels of
resistance [16].
Prevention of Anemia, Severe Illness, and Death
Besides reducing the burden of malaria episodes, IPTi also
reduced the risk of moderate-to-severe anemia (25% in the mITT
and 34%–41% in the ATP analyses, respectively) and severe
anemia (51%–87%). These effects are in line with previous
findings on the prevention of anemia in Africa [10].
No difference was observed between the groups in number of
SAEs (i.e., all cause admissions plus severe illness). Surprisingly, a
significantly lower death rate was observed in the two treatment
arms compared to the placebo arm. Even though this finding is
very encouraging, it must be interpreted with caution. The present
study was not powered to observe an effect of IPTi on mortality,
and in the meta-analysis of six African studies, no effect of IPTi
with SP on mortality was detected [10]. Only seven deaths
occurred during the intervention period, with most children dying
at home. Based on verbal autopsies and available clinical records,
Figure 3. Prevalence of P. falciparum and P. vivax infections during follow-up by treatment group (light microscopy) and overall
(PCR). * p,0.05.
doi:10.1371/journal.pmed.1001195.g003
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a majority of children might have died of severe lower respiratory
tract infections and not from malaria.
Safety of SP-AQ and SP-AS
IPTi with SP-AQ or SP-AS was very safe. More than 4,000
doses of SP and 6,000 doses of AQ and AS were given, and no
study-drug-related SAEs were observed, while AEs such as
vomiting were rare in all groups. As reported in earlier studies,
no significant increase in risk of malaria or anemia was recorded
in the 6 mo after completion of the 12 mo of IPTi, indicating
that IPTi does not impair the acquisition of immunity to both Pf
and Pv and lead to a rebound in malaria risk. These data are
very reassuring in regard to a possible use of these drug
combinations in PNG and add to the safety data from African
IPTi studies [10].
The use of SP as prophylaxis has been criticized because of the
potential risk of Stevens-Johnson syndrome, a severe skin reaction
[52], but by now .15,000 children have been treated with SP-
containing IPTi regimens in well-controlled clinical trials, and not
a single drug-related severe dermatological event has been
observed [10,16,34,53]. On the other hand, IPTi with mefloquine
was highly effective, but was not well tolerated, with high rates of
vomiting [16]. In the absence of novel drug regimens for IPTi, the
combination of SP and AQ is the best currently available option
for IPTi in PNG.
Adherence, Acceptability, and Implementation
The size of the difference in IPTi efficacy between the ATP and
mITT analyses indicates that if the intervention is implemented, it
will be important to achieve high coverage and high adherence in
order to achieve good effectiveness.
In both the SP-AQ and SP-AS groups only the first dose was
given as directly observed treatment. Parents were then counseled
on the importance of giving the remaining two doses at home.
With this approach a very high rate of compliance (.90%) was
achieved. As a result, SP and AQ day 4 drug levels were found to
be comparable (N. Senn, P. Rarau, and I. Mueller, unpublished
data) to those found in pharmacological studies with directly
observed drug administration [50,54]. Acceptability of IPTi by
parents and health workers of IPTi was excellent, and the
administration of IPTi alongside EPI did not have negative
impacts on attitudes to EPI, EPI adherence, or existing malaria
prevention practices [55]. Therefore, and consistent with what was
described in Africa [53], the IPTi intervention seems to be well
suited for implementation in community settings in PNG, with
high likelihood of both acceptability and adherence.
Conclusion
This study provides evidence of the efficacy of IPTi for the
prevention of malaria and anemia in a region highly endemic for
both Pf and Pv. Additionally, this study provides an essential proof
of principle that IPTi is an appropriate strategy for the prevention
of Pv malaria, if an effective, long half-life drug is used. Policy
makers should therefore consider IPTi in areas outside Africa or in
countries in the Horn of Africa, where the burden of Pv malaria is
high. Which areas are suited for IPTi introduction will depend on
transmission level and choice of drug, both of which will affect the
cost-effectiveness of the intervention [56]. While the results from
Africa indicate that IPTi is a highly cost-effective intervention even
at moderate levels of transmission [57], a formal evaluation of
IPTi cost-effectiveness in non-African settings will be required to
assist policy makers. Given the levels of resistance to SP and AQ in
many parts of the Asia-Pacific and Americas, further studies are
needed to investigate other combinations of long-acting drugs with
a better efficacy against Pv, in particular.
In the PNG context, the combination of SP-AQ (two long-
acting drugs with well-matched half-lives and good activity against
either Pf [SP] or Pv [AQ]) is an appropriate drug choice for IPTi,
and its introduction into the national standard treatment
guidelines should be considered. The replacement of AQ and
SP by artemether-lumefantrine as the national first line treatment
will reduce the selection pressure for resistance against AQ and SP.
Therefore, the efficacy of the two drugs in IPTi may be retained
over time. Appropriate monitoring of prophylactic efficacy of AQ
and SP, as well as evaluating new regimens, such as dihydroarte-
misinin-piperaquine, should accompany IPTi introduction in
PNG.
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Editors’ Summary
Background Malaria is a major global public health pro-
blem. Half the world’s population is at risk of this parasitic
disease, which kills about one million people (mainly young
children in sub-Saharan Africa) every year. Most of these
deaths are caused by Plasmodium falciparum but P. vivax, the
commonest and most widely distributed malaria parasite, is
a major cause of malaria-related morbidity (illness and death)
in many of the tropical and subtropical regions of the world
where malaria is endemic (always present). Malaria is trans-
mitted to people through the bites of night-flying mos-
quitoes. It can be prevented by controlling the mosquitoes
that spread the parasite and by sleeping under insecticide-
treated nets to avoid mosquito bites. Prompt treatment
of malaria with antimalarial drugs can also reduce malaria
transmission. In addition, intermittent preventative treatment
(IPT)—the treatment of symptom-free individuals with full
therapeutic courses of antimalarial drugs at fixed intervals
regardless of their infection status—has been shown to
reduce malaria-related morbidity among pregnant women in
malaria-endemic areas and among African infants living in
areas of high P. falciparum transmission.
Why Was This Study Done? The World Health
Organization recently recommended that, in Africa, IPT
should be given during infancy (called IPTi) at the same
time as routine immunizations. Because the studies on which
this recommendation is based were all carried out in sub-
Saharan Africa, in populations where P. falciparum is the
predominant parasite and P. vivax is uncommon, it is not
known whether IPTi would be an appropriate prevention
strategy in non-African settings or in regions where both P.
falciparum and P. vivax are endemic. In this randomized
placebo-controlled trial, the researchers investigate the
efficacy of IPTi in infants living in an area of Papua New
Guinea where P. falciparum and P. vivax are both highly
endemic. In a randomized placebo-controlled trial, the effects
of an intervention and of a placebo (dummy) intervention are
compared in groups of individuals chosen through the play
of chance.
What Did the Researchers Do and Find? The researchers
assigned more than 1,000 infants to receive sulfadoxine/
pyrimethamine (SP) plus amodiaquine (AQ) (SP and AQ are
long-lasting antimalarial drugs), SP plus artesunate (AS) (AS is
a short-lasting antimalarial), or placebo at 3, 6, 9, and 12
months old. They recorded the number of malaria episodes
that occurred among the children between the ages of 3 and
15 months. Then, by comparing the number of episodes
occurring among the children receiving SP-AS or SP-AQ with
the number occurring among the children receiving placebo,
the researchers calculated the protective efficacy of the two
drug combinations over the study period. The protective
efficacy of IPTi against all clinical malaria episodes (P.
falciparum and P. vivax combined) was 29% for SP-AQ, but
SP-AS was not associated with a statistically significant
reduction in all malaria episodes as compared to placebo.
For the two species of malaria separately, the incidence of P.
falciparum malaria was 35% lower among the children
receiving SP-AQ than among the children receiving placebo,
whereas the incidence of P. vivax was reduced by 23%; IPTi
with SP-AS provided protection only against P. falciparum
malaria (protective efficacy 31%). Importantly, the number of
adverse events (possible drug side effects) was similar in all
the treatment arms, none of the severe adverse events were
treatment-related, and there was no rebound in malaria-
related morbidity for six months following the end of the
intervention.
What Do These Findings Mean? These findings show that
IPTi using a combination of long-lasting antimalarial drugs
(SP-AQ) can effectively and safely prevent malaria in a non-
African population living in a region where P. falciparum and
P. vivax are both highly endemic. Importantly, they also show
that IPTi with SP-AQ can prevent both P. falciparum and P.
vivax malaria. For Papua New Guinea, these findings suggest
that SP-AQ is an appropriate drug choice for IPTi, particularly
since the replacement of SP-AQ by artemether-lumefantrine
as the national first line treatment for malaria will reduce the
selection pressure for resistance against SP and AQ. However,
although these finding provide proof-of-principle evidence for
the efficacy and safety of IPTi, further studies are needed
to identify the most effective combinations of long-lasting
antimalarial drugs for use in IPTi in other malaria-endemic
regions.
Additional Information Please access these web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001195.
N Information is available from the World Health Organiza-
tion on malaria (in several languages); the 2011 World
Malaria Report provides details of the current global
malaria situation; and the WHO policy recommendation on
IPTi for P. falciparum malaria control in Africa is available
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish), including
a selection of personal stories about malaria
N Information is available from the Roll Back Malaria
Partnership on the global control of malaria, including a
fact sheet about malaria in children and information on
malaria in Papua New Guinea
N The IPTi Consortium was established to evaluate IPTi and
inform public health policy making
N The Malaria Vaccine Initiative has a fact sheet on P. vivax
malaria
N Vivaxmalaria.com provides information about P. vivax
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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